Biogen Reports Progress on Corporate Responsibility Priorities
02 May 2024 - 9:30PM
Biogen Inc. (Nasdaq: BIIB) today announced publication of its 2023
Corporate Responsibility Report detailing progress on the company’s
commitment to making responsible business decisions in the best
interests of all its stakeholders.
“As we reflect on the past year and set our sights on the path
ahead, I am truly inspired by the progress we have made to advance
Biogen’s enduring legacy of pioneering innovative science to
deliver medicines that transform patients’ lives and create value
for our communities and our shareholders,” said Christopher A.
Viehbacher, Biogen President and Chief Executive Officer. “Our
mission and business strategy are grounded in our commitment to
responsible business, and in 2023, we refined our corporate
responsibility strategy to advance our evolving business priorities
and align with areas where we believe we can have the greatest
impact.”
The Corporate Responsibility Report details progress across four
key pillars:
- Access & Health Equity: Added four
first-in-class medicines to the portfolio, LEQEMBI®, QALSODY®,
SKYCLARYS® and ZURZUVAE™ and expanded access to SPINRAZA®, which is
now available in 70 countries, for people living with spinal
muscular atrophy. Realized a 35% increase in the number of patients
with access to tofersen through Biogen’s Early Access Program. In
2023, 89% of clinical trials delivered race and ethnicity
enrollment targets that reflect the epidemiology of the
disease.
- Workforce & DE&I: Increased focus on
employee engagement, spirit of innovation and culture while
building on our strengths with a results-oriented mindset. In its
annual internal survey, 81% of participating employee respondents
said they have a sense of purpose by doing meaningful work at
Biogen. Also fostered an employee base reflective of the broader
workforce, with 48.6% of roles at the Director level and above
globally held by women and 31.2% racial/ethnic representation
across U.S. roles at the Manager level and above.
- Community Impact: Continued to make meaningful
contributions to local communities. In 2023, Biogen refreshed its
flagship science education program, which has reached more than
64,000 students since 2002, under the new CoLab name, expanding its
reach and partnerships. Through the Biogen Foundation, worked to
address social determinants of health, such as food security and
access to healthcare, investing $4.37 million in grants and
providing more than 750,000 meals to local families. Employees
volunteered more than 10,000 hours.
- Environment: Revised environmental strategy,
deepening the focus on efficiencies that can deliver both cost
savings and environmental benefits. In 2023, Biogen was the first
large biotech to certify 100% of its labs through My Green Lab, a
program recognized by the United Nations Race to Zero campaign as
the leading standard for laboratory sustainability. In addition,
the company maintained a commitment to 100% renewable electricity
across its sites and facilities. Biogen also conducted four life
cycle assessments of how its products impact the environment.
The 2023 Corporate Responsibility Report is aligned
with GRI, SASB, the Task Force on Climate-Related
Financial Disclosures (TCFD) and reflects its commitment to
the U.N. Sustainable Development Goals (SDGs).
To access the full report and learn more about Biogen's
corporate responsibility initiatives, visit
http://www.biogen.com/esgreport.
About BiogenFounded in 1978, Biogen is a
leading biotechnology company that pioneers innovative science to
deliver new medicines to transform patients’ lives and to create
value for shareholders and our communities. We apply deep
understanding of human biology and leverage different modalities to
advance first-in-class treatments or therapies that deliver
superior outcomes. Our approach is to take bold risks, balanced
with return on investment to deliver long-term growth.We routinely
post information that may be important to investors on our website
at www.biogen.com. Follow us on social
media - Facebook, LinkedIn, X, YouTube.
Biogen Safe Harbor This press release
contains forward-looking statements, relating to: our strategy and
plans; potential of, and expectations for, our commercial business
and pipeline programs; corporate responsibility strategy, capital
allocation and investment strategy; clinical development programs,
clinical trials, and data readouts and presentations; regulatory
discussions, submissions, filings, and approvals; the potential
benefits, safety, and efficacy of our and our collaboration
partners’ products and investigational therapies; the anticipated
benefits and potential of investments. These forward-looking
statements may be accompanied by such words as “aim,” “anticipate,”
“believe,” “could,” “estimate,” “expect,” “forecast,” “goal,”
“intend,” “may,” “plan,” “potential,” “possible,” “prospect,”
“will,” “would,” and other words and terms of similar meaning. Drug
development and commercialization involve a high degree of risk,
and only a small number of research and development programs result
in commercialization of a product. Results in early-stage clinical
trials may not be indicative of full results or results from later
stage or larger scale clinical trials and do not ensure regulatory
approval. You should not place undue reliance on these
statements.
These statements involve risks and uncertainties that could
cause actual results to differ materially from those reflected in
such statements, including: our dependence on sales from our
products; uncertainty of long-term success in developing,
licensing, or acquiring other product candidates or additional
indications for existing products; failure to compete effectively;
failure to successfully execute or realize the anticipated benefits
of our strategic and growth initiatives; difficulties in obtaining
and maintaining adequate coverage, pricing, and reimbursement for
our products; our dependence on collaborators and other third
parties for the development, regulatory approval, and
commercialization of products and other aspects of our business,
which are outside of our full control; risks associated with
current and potential future healthcare reforms; risks related to
commercialization of biosimilars; failure to obtain, protect, and
enforce our data, intellectual property, and other proprietary
rights and the risks and uncertainties relating to intellectual
property claims and challenges; the risk that positive results in a
clinical trial may not be replicated in subsequent or confirmatory
trials or success in early stage clinical trials may not be
predictive of results in later stage or large scale clinical trials
or trials in other potential indications; risks associated with
clinical trials, including our ability to adequately manage
clinical activities, unexpected concerns that may arise from
additional data or analysis obtained during clinical trials,
regulatory authorities may require additional information or
further studies, or may fail to approve or may delay approval of
our drug candidates; the occurrence of adverse safety events,
restrictions on use with our products, or product liability claims;
risks relating to technology failures or breaches; problems with
our manufacturing processes; risks relating to management,
personnel and other organizational changes, including attracting
and retaining personnel; failure to comply with legal and
regulatory requirements; the risks of doing business
internationally, including currency exchange rate fluctuations;
risks relating to investment in our manufacturing capacity; risks
relating to the distribution and sale by third parties of
counterfeit or unfit versions of our products; risks relating to
the use of social media and artificial intelligence based software
for our business; results of operations, and financial condition;
fluctuations in our operating results; risks related to investment
in properties; risks relating to access to capital and credit
markets; risks related to indebtedness; the market, interest, and
credit risks associated with our investment portfolio; risks
relating to share repurchase programs; change in control provisions
in certain of our collaboration agreements; fluctuations in our
effective tax rate; environmental risks; and any other risks and
uncertainties that are described in other reports we have filed
with the U.S. Securities and Exchange Commission. These statements
speak only as of the date of this press release. We do not
undertake any obligation to publicly update any forward-looking
statements.
MEDIA CONTACT:BiogenJack Cox+ 1 781 464
3260public.affairs@biogen.com |
INVESTOR CONTACT:BiogenChuck Triano+1 781 464
2442IR@biogen.com |
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From Apr 2024 to May 2024
Biogen (NASDAQ:BIIB)
Historical Stock Chart
From May 2023 to May 2024